NCT00481325

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 260 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: Female
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to learn about the safety and efficacy of pexacerfont in outpatients diagnosed with Generalized Anxiety Disorder

Conditions

• Generalized Anxiety Disorder

Interventions

Type	Name	Description
DRUG	pexacerfont	Tablets \& Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks
DRUG	escitalopram	Tablets \& Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks
DRUG	placebo	Tablets \& Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks

Timeline

• Start date: 2007-07-01
• Primary completion: 2008-03-01
• Completion: 2008-03-01
• First posted: 2007-06-01
• Last updated: 2015-10-12

Locations

51 sites across 1 country: United States